Literature DB >> 10226538

Expression of the G2-M checkpoint regulators cyclin B1 and P34CDC2 in breast cancer: a correlation with cellular kinetics.

T Megha1, S Lazzi, F Ferrari, R Vatti, C M Howard, G Cevenini, L Leoncini, P Luzi, A Giordano, P Tosi.   

Abstract

In this study, the expression of cyclin B1 and p34cdc2 in neoplastic and non-neoplastic breast lesions was evaluated by immunohistochemistry and quantitative analysis in relation to cellular kinetic parameters such as Mitotic Index (MI), Anatelophase Index (ATI), and Apoptotic Index (AI). The percentage of cyclin B1 and p34cdc2-positive cells was significantly higher in neoplastic glands than in their normal counterparts. This finding was paralleled by significantly higher values of MI, ATI, and AI in breast cancer than in normal glands. Furthermore, two groups with different cytokinetic characteristics were identified among infiltrating ductal carcinomas by an unsupervised learning technique of cluster analysis using the percentages of cyclin B1 and p34cdc2 positive cells and the cellular kinetic parameters (MI, ATI and AI) as variables. The final clusters, groups I and II, consisted of 42 and 13 cases respectively. The first cluster (group I) was characterized by a significantly linear correlation between the percentages of cyclin B1 and p34cdc2-positive cells. On the contrary, the second cluster (group II) revealed no correlation between these two proteins and was characterized by values of p34cdc2 largely exceeding those of cyclin B1. A positive correlation between the expression of these two proteins and the cellular kinetic parameters (MI, ATI and AI) was also found in group I but not in group II. These observations suggest that a disturbed nuclear translocation of Mitosis Promoting Factor (MPF) components is present in group II cases, resulting in a defective cellular division cycle. In fact, group I cases showed lymph node metastasis more frequently than group II cases. Our results suggest that the analysis of the cell cycle "machinery" components, such as the cyclins and their dependent kinases, can identify tumors with different levels of aggressiveness.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10226538

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Quercetin inhibits the invasion and mobility of murine melanoma B16-BL6 cells through inducing apoptosis via decreasing Bcl-2 expression.

Authors:  X Zhang; Q Xu; I Saiki
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Identification of molecular markers for metastasis-related genes in primary breast cancer cells.

Authors:  Koshi Mimori; Akemi Kataoka; Keiji Yoshinaga; Mitsuhiko Ohta; Yasuaki Sagara; Yasuji Yoshikawa; Shinji Ohno; Graham F Barnard; Masaki Mori
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  PAK1-Nck regulates cyclin D1 promoter activity in response to prolactin.

Authors:  Jing Tao; Peter Oladimeji; Leah Rider; Maria Diakonova
Journal:  Mol Endocrinol       Date:  2011-06-30

4.  Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins.

Authors:  Simen Myhre; Ole-Christian Lingjærde; Bryan T Hennessy; Miriam R Aure; Mark S Carey; Jan Alsner; Trine Tramm; Jens Overgaard; Gordon B Mills; Anne-Lise Børresen-Dale; Therese Sørlie
Journal:  Mol Oncol       Date:  2013-03-19       Impact factor: 6.603

5.  Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.

Authors:  H P Kourea; A K Koutras; C D Scopa; M N Marangos; E Tzoracoeleftherakis; D Koukouras; H P Kalofonos
Journal:  Mol Pathol       Date:  2003-12

6.  Harmine activates intrinsic and extrinsic pathways of apoptosis in B16F-10 melanoma.

Authors:  Thayele Purayil Hamsa; Girija Kuttan
Journal:  Chin Med       Date:  2011-03-23       Impact factor: 5.455

7.  Adaptation to statins restricts human tumour growth in Nude mice.

Authors:  Julie Follet; Lionel Rémy; Vincent Hesry; Brigitte Simon; Danièle Gillet; Pierrick Auvray; Laurent Corcos; Catherine Le Jossic-Corcos
Journal:  BMC Cancer       Date:  2011-11-22       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.